|
|
Blood, 1 February 2006, Vol. 107, No. 3, pp. 859-861.
Prepublished online as a Blood First Edition Paper on October 13, 2005; DOI 10.1182/blood-2005-04-1677.
 Previous Article | Table of Contents | Next Article 
PERSPECTIVES
Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia
Jacques-Louis Binet,
Federico Caligaris-Cappio,
Daniel Catovsky,
Bruce Cheson,
Tom Davis,
Guillaume Dighiero,
Hartmut Döhner,
Michael Hallek,
Peter Hillmen,
Michael Keating,
Emili Montserrat,
Thomas J. Kipps,
Kanti Rai, for the International Workshop on Chronic Lymphocytic Leukemia (IWCLL)-initiated working group on prognostic and diagnostic parameters in CLL
From the Rebecca and John Moores Cancer Center, University of California, San Diego, La Jolla, CA; the Klinik I für Innere Medizin, Universität zu Köln, Köln, Germany; the Hospital de La Salpetriere, Centre d'Ecologie Cellulaire, Paris, France; the Universita Vita-Salute San Raffaele, Milano, Italy; the Institute of Cancer Research, London, United Kingdom; the Georgetown University Hospital, Lombardi Cancer Center, Washington, DC; the National Institutes of Health, Office of The Director, Bethesda, MD; the Institute Pasteur, Paris, France; the University of Ulm, Ulm, Germany; the Pinderfields Hospital, Wakefield, United Kingdom; the Department. of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX; the Hospital Clinic, Barcelona, Spain; and the Division of Hematology/Oncology, Long Island Jewish Medical Center, New Hyde Park, NY.
Abstract
Recently, considerable progress has been made in the identification of molecular and cellular markers that may predict the tendency for disease progression in patients with chronic lymphocytic leukemia (CLL) or detect minimal residual disease after therapy. These developments have created uncertainty for clinicians who hope to incorporate the use of these markers and new disease-assessment tools into standard clinical practice. However, clinical trials are required to determine whether poor-prognosis leukemia-cell markers, such as expression of unmutated immunoglobulin genes or the zeta-associated protein of 70 kDa (ZAP-70), can be used as the basis for determining the time or type of therapy. Pending the outcome of such trials, treatment decisions outside the context of a clinical trial still should be based on guidelines established by the most recent National Cancer Institute-sponsored Working Group.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
D. Dierickx, A. De Rycke, P. Vandenberghe, A. Janssens, E. Lerut, C. De Wolf-Peeters, G. Verhoef, and P. Evenepoel
Recipient-derived chronic lymphocytic leukaemia diagnosed shortly after kidney transplantation on protocol biopsy
Nephrol. Dial. Transplant.,
September 3, 2009;
(2009)
gfp444v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Eichhorst, M. Hallek, M. Dreyling, and On behalf of the ESMO Guidelines Working Group
Chronic lymphocytic leukemia: ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up
Ann. Onc.,
May 1, 2009;
20(suppl_4):
iv102 - iv104.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Hernandez, A. E. Rodriguez, M. Gonzalez, R. Benito, C. Fontanillo, V. Sandoval, M. Romero, G. Martin-Nunez, A. G. de Coca, R. Fisac, et al.
A high number of losses in 13q14 chromosome band is associated with a worse outcome and biological differences in patients with B-cell chronic lymphoid leukemia
Haematologica,
March 1, 2009;
94(3):
364 - 371.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. J. Kipps
Chronic Lymphocytic Leukemia: Advances in Assessing Prognosis and Therapy
ASCO Educational Book,
January 1, 2009;
2009(1):
385 - 393.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Roue, M. Lopez-Guerra, P. Milpied, P. Perez-Galan, N. Villamor, E. Montserrat, E. Campo, and D. Colomer
Bendamustine Is Effective in p53-Deficient B-Cell Neoplasms and Requires Oxidative Stress and Caspase-Independent Signaling
Clin. Cancer Res.,
November 1, 2008;
14(21):
6907 - 6915.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Rossi, A. Zucchetto, F. M. Rossi, D. Capello, M. Cerri, C. Deambrogi, S. Cresta, S. Rasi, L. De Paoli, C. L. Bodoni, et al.
CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia
Haematologica,
October 1, 2008;
93(10):
1575 - 1579.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Z. Rassenti, S. Jain, M. J. Keating, W. G. Wierda, M. R. Grever, J. C. Byrd, N. E. Kay, J. R. Brown, J. G. Gribben, D. S. Neuberg, et al.
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia
Blood,
September 1, 2008;
112(5):
1923 - 1930.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Baskar, K. Y. Kwong, T. Hofer, J. M. Levy, M. G. Kennedy, E. Lee, L. M. Staudt, W. H. Wilson, A. Wiestner, and C. Rader
Unique Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Human B-Cell Chronic Lymphocytic Leukemia
Clin. Cancer Res.,
January 15, 2008;
14(2):
396 - 404.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. W. Hauswirth and U. Jager
Impact of cytogenetic and molecular prognostic markers on the clinical management of chronic lymphocytic leukemia
Haematologica,
January 1, 2008;
93(1):
14 - 19.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Fernandez, P. Jares, I. Salaverria, E. Gine, S. Bea, M. Aymerich, D. Colomer, N. Villamor, F. Bosch, E. Montserrat, et al.
Gene expression profile and genomic changes in disease progression of early-stage chronic lymphocytic leukemia
Haematologica,
January 1, 2008;
93(1):
132 - 136.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. J. Kipps
Chronic Lymphocytic Leukemia: Prognostic Markers and Revised Criteria for Treatment and Response Assessment
ASCO Educational Book,
January 1, 2008;
2008(1):
286 - 290.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. J. Kipps
Value of Computed Tomography in the Monitoring of Patients With Chronic Lymphocytic Leukemia
J. Clin. Oncol.,
December 10, 2007;
25(35):
5556 - 5556.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Tsimberidou, S. Wen, S. O'Brien, P. McLaughlin, W. G. Wierda, A. Ferrajoli, S. Faderl, J. Manning, S. Lerner, C. V. Mai, et al.
Assessment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma by Absolute Lymphocyte Counts in 2,126 Patients: 20 Years of Experience at The University of Texas M.D. Anderson Cancer Center
J. Clin. Oncol.,
October 10, 2007;
25(29):
4648 - 4656.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Molica, M. Montillo, D. Ribatti, R. Mirabelli, A. Tedeschi, F. Ricci, S. Veronese, A. Vacca, and E. Morra
Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia
Haematologica,
October 1, 2007;
92(10):
1367 - 1374.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Josefsson, C. H. Geisler, H. Leffers, J. H. Petersen, M. K. Andersen, J. Jurlander, and A. M. Buhl
CLLU1 expression analysis adds prognostic information to risk prediction in chronic lymphocytic leukemia
Blood,
June 1, 2007;
109(11):
4973 - 4979.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Grever, D. M. Lucas, G. W. Dewald, D. S. Neuberg, J. C. Reed, S. Kitada, I. W. Flinn, M. S. Tallman, F. R. Appelbaum, R. A. Larson, et al.
Comprehensive Assessment of Genetic and Molecular Features Predicting Outcome in Patients With Chronic Lymphocytic Leukemia: Results From the US Intergroup Phase III Trial E2997
J. Clin. Oncol.,
March 1, 2007;
25(7):
799 - 804.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. D. Shanafelt, J. C. Byrd, T. G. Call, C. S. Zent, and N. E. Kay
Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia.
Ann Intern Med,
September 19, 2006;
145(6):
435 - 447.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. W. L. Yee and S. M. O'Brien
Chronic Lymphocytic Leukemia: Diagnosis and Treatment
Mayo Clin. Proc.,
August 1, 2006;
81(8):
1105 - 1129.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
